
Model-Informed Drug Development

2021 Virtual Conference

Introduction to Phase II Track Joel S. Owen, Ph.D. Vice President, Pharmacometric Services



Drug Development Phases



2021 Virtual Conference

Application of Modeling & Simulation in Phase 2

Questions to be Addressed

- Can we develop predictive quantitative models for safety and efficacy endpoints
- Can we confirm mechanisms of action; clinical utility and validation potential of biomarkers
- What is the best dose and study design for the subsequent Phase 3 trials

Model-Informed Drug Development

Validate Population PK Model

Develop PD models for safety and efficacy Determine Phase 3 Dose

Explore biomarker roles; confirm mechanisms

Modeling & Simulation Tasks



Phase 2 Panelists

Claude Magnard, PhD Application Manager Simulations Plus, Inc. Investigation of the power of a phase III trial for different sample sizes via clinical trial simulations using a phase II population PD model

Sebastien Bihorel, PharmD, PhD Director, Pharmacometrics and Workflow Automation Simulations Plus, Inc. Pharmacometrics in Phase 2 - PoC and Dose Selection for Phase 3/Marketing

Yaning Wang, PhD Director, Division of Pharmacometrics, Office of Clinical Pharmacology U.S. Food and Drug Administration The impact of MIDD during phase 2 of new drug development - a Regulatory Perspective



Zack Kenz, PhD Scientist II Simulations Plus, Inc. Mathematical Modeling with NAFLDsym® Supports the Role of Adiponectin in the Reduction of Steatosis by the Anti FGFR1/KLB Bispecific Antibody





Phase 3 Poster Presenters



David Jaworowicz, PhD Senior Director, Pharmacometrics Simulations Plus, Inc. Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine Bone Mineral Density in Two Phase II Studies of Postmenopausal Women

Julie Passarell, MA Assistant Vice President, Statistics Simulations Plus, Inc. Exposure-Response Modeling from the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder





Model-Informed Drug Development

2021 Virtual Conference



Learn More! www.simulations-plus.com

SF SimulationsPlus Cognigen | DILIsym Services | Lixoft